Breaking Finance News

Stifel disclosed BTG PLC (LON:BTG), retaining its price target at 640.00GBX earlier today

Yesterday BTG PLC (LON:BTG) traded 5.10% higher at 679.25GBX. The company’s 50-day moving average is 626.72GBX and its 200-day moving average is 640.49GBX. The last closing price is up 6.17% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 407,953 shares of the stock traded hands, down from an average trading volume of 593,485

Reporting a potential downside of -0.06%, Stifel hold steady the stock price target of BTG PLC (LON:BTG) at 640.00GBX

See Chart Below


BTG PLC has a price-earnings ratio of 43.59 with a one year low of 504.00GBX and a one year high of 739.50GBX The company’s market cap is currently 0 GBX.


BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.